ArticleNature2021
Ebola virus antibody decay-stimulation in a high proportion of survivors.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 44 citations in OpenAlex.
- Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.NPJ vaccines · 2026Article
- Identification of a unique humoral immune signature of Sudan ebolavirus persistence in human survivors.Research square · 2026Article
- Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease.BMC infectious diseases · 2026Article
- Viral RNA persistence and long-term consequences following acute infection with Risk Group 4 zoonotic viruses.Frontiers in cellular and infection microbiology · 2026Review
- Assessing Ebola virus circulation in the Tshuapa province (Democratic Republic of the Congo): A One Health investigation of wildlife and human interactions.PLoS pathogens · 2025Article
- Viral persistence in long COVID: Research advances and treatment strategies.Infectious diseases & immunity · 2025Review
- Where is the elusive primaryBioscience · 2025Article
- Antibody-Based Antigen Delivery to Dendritic Cells as a Vaccination Strategy Against Ebola Virus Disease.The Journal of infectious diseases · 2025Article
- Ebola Virus-Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean Cohort.The Journal of infectious diseases · 2024Article
- Development of a pseudo-typed virus particle based method to determine the efficacy of virucidal agents.Scientific reports · 2024Article
- The ecology of viruses in urban rodents with a focus on SARS-CoV-2.Emerging microbes & infections · 2023Article
- Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.NPJ vaccines · 2023Article
- SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC).Nature immunology · 2023Review
- A Quantitative Method for the Study of HIV-1 and Mycobacterium tuberculosis Coinfection.The Journal of infectious diseases · 2023Article
- Post-Ebola Symptoms 7 Years After Infection: The Natural History of Long Ebola.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Pseudotyped Viruses for Marburgvirus and Ebolavirus.Advances in experimental medicine and biology · 2023Article
- SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study.Frontiers in immunology · 2023Article
- RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease.Pathogens (Basel, Switzerland) · 2022Review
- Article
- Why does viral RNA sometimes persist after recovery from acute infections?PLoS biology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 19 institutions in 6 countries.
Charlene Adaken *Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, UK.
Janet T Scott *NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU EZI), University of Liverpool, Liverpool, UK.
Raman Sharma *Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, UK.
Robin GopalHigh Containment Microbiology, National Infections Service, Public Health England, London, UK.
Steven DicksBlood Borne Virus Unit, National Infection Service, Public Health England, London, UK.ORCID http://orcid.org/0000-0002-4709-9664
Saidia NiaziBlood Borne Virus Unit, National Infection Service, Public Health England, London, UK.
Samreen IjazBlood Borne Virus Unit, National Infection Service, Public Health England, London, UK.
Tansy EdwardsMRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
Catherine C SmithFaculty of Health and Life Science, University of Liverpool, Liverpool, UK.
Christine P ColeCollege of Medicine and Allied Health Sciences, Freetown, Sierra Leone.
Philip KamaraNational Safe Blood Service, Ministry of Health and Sanitation, Freetown, Sierra Leone.
Osman KargboNational Safe Blood Service, Ministry of Health and Sanitation, Freetown, Sierra Leone.
Heidi A DoughtyNational Health Service Blood and Transplant, Birmingham, UK.
Johan van GriensvenInstitute of Tropical Medicine, Antwerp, Belgium.
Peter W HorbyCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Sahr M GevaoNational Safe Blood Service, Ministry of Health and Sanitation, Freetown, Sierra Leone.
Foday SahrCollege of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
Ebola-CP Consortium
Richard J DimelowGlaxoSmithKline, Stevenage, UK.
Richard S TedderNIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU EZI), University of Liverpool, Liverpool, UK.
Malcolm G SempleNIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU EZI), University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0001-9700-0418
William A PaxtonDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0001-5200-0801
Georgios PollakisDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, UK. g.pollakis@liverpool.ac.uk.ORCID http://orcid.org/0000-0002-9659-5461
University of Liverpool · GBUniversity of Sierra Leone · SLNational Health Service · GBInstituut voor Tropische Geneeskunde · BEMinistry of Health and Sanitation · SLLondon School of Hygiene & Tropical Medicine · GBPublic Health England · GBUniversity of Oxford · GBKing's College London · GBUniversity of North Carolina at Chapel Hill · USWorld Health Organization · CHBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEClinical Research Management · USDuke University · USGlaxoSmithKline (United Kingdom) · GBLiverpool School of Tropical Medicine · GBRoslin Institute · GBSierra Leone Urban Research Centre · SLUniversity of Exeter · GB
Funding
Medical Research Council MC_UU_12014/8Medical Research Council MR/R010161/1Wellcome TrustWellcome Trust 106491
Abstract
Neutralizing antibody function provides a foundation for the efficacy of vaccines and therapies
Indexed as
ConvalescenceSurvivorsAdolescentAdultAfrica, WesternAntibodies, NeutralizingAntibodies, ViralCohort StudiesEbolavirusFemaleHalf-LifeHemorrhagic Fever, EbolaHumansMaleMiddle AgedNeutralization TestsAntibodies, NeutralizingAntibodies, Viral
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.